Q-omics provides the consensus-scored ATP5F1EP2 profile across patient tissues and cancer cell-line models. ATP5F1EP2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ATP5F1EP2 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, ATP5F1EP2 RNA expression shows 16,780 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, COAD, and THYM as cancer lineages where ATP5F1EP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATP5F1EP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATP5F1EP2 survival associations across molecular data types. ATP5F1EP2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATP5F1EP2 RNA expression–survival associations across cancer types. High ATP5F1EP2 expression shows unfavorable associations in UVM, ACC, LUAD, LIHC and BRCA, but favorable associations in THCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ATP5F1EP2 RNA expression.
This table summarizes ATP5F1EP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ATP5F1EP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATP5F1EP2 shows higher tumor expression in COAD, UCEC, BRCA, LIHC, STAD and CHOL. The COAD box plot shows higher ATP5F1EP2 RNA expression in tumor versus normal tissue (log2 FC = +2.241, t-test p < 0.001).
This table shows molecular features associated with ATP5F1EP2 in patient tissues and cancer cell lines. In patient samples, ATP5F1EP2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
